The burden of suboptimal breastfeeding in the United States: a pediatric cost analysis

Melissa Bartick1, Arnold Reinhold

  • 1Department of Medicine, Cambridge Health Alliance and Harvard Medical School, Boston, Massachusetts, USA. melissabartick@gmail.com

Pediatrics
|April 7, 2010
PubMed

Insights

Increasing breastfeeding rates could save billions and prevent thousands of infant deaths annually. Promoting exclusive breastfeeding for six months offers significant public health and economic benefits.

Area of Science:

  • Public Health Economics
  • Pediatric Health Outcomes
  • Maternal and Child Health

Background:

  • Previous studies estimated substantial cost savings from increased breastfeeding rates.
  • Current breastfeeding rates in the US remain suboptimal, leading to preventable health issues and economic burdens.

Purpose of the Study:

  • To update the economic impact of breastfeeding by analyzing current rates and a broader range of pediatric diseases.
  • To project cost savings and mortality reductions associated with achieving higher exclusive breastfeeding rates.

Main Methods:

  • Cost analysis adapted from a 2001 study, using 2005 breastfeeding rates and 2007 dollars.
  • Included pediatric diseases with documented breastfeeding benefits from Agency for Healthcare Research and Quality data.
  • Calculated costs for 80% and 90% compliance with exclusive breastfeeding for six months.

Main Results:

  • Achieving 90% exclusive breastfeeding for six months could save $13 billion annually and prevent 911 deaths.
  • At 80% compliance, savings would reach $10.5 billion with 741 lives saved, primarily infants.
  • Current suboptimal rates incur significant excess costs and preventable infant mortality.

Conclusions:

  • Suboptimal breastfeeding rates in the US result in substantial economic losses and preventable infant deaths.
  • Investing in strategies to promote longer breastfeeding duration and exclusivity is likely cost-effective.
  • Public health initiatives supporting breastfeeding are crucial for improving child health and reducing healthcare expenditures.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
250
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218